Post-transplant Test for Kidney Acute Rejection (VitaGraft™, Tuteva™)
Each year, over 100,000 individuals worldwide undergo kidney transplantation to manage ESRD. Despite advances in immunosuppressive therapy (e.g., cyclosporine, tacrolimus, anti-thymocyte globulin), acute rejection remains a critical barrier to long-term graft survival, affecting approximately 10–20% of transplant recipients within the first year.
The current gold standard for diagnosing acute rejection is a renal biopsy, often combined with monitoring serum creatinine and urea levels. However, these methods are invasive, carry procedural risks, and lack early predictive power.
Tuteva™ is a non-invasive, blood-based molecular test developed by VericiDx. It assesses the risk of acute kidney rejection by measuring gene expression profiles in peripheral blood using next-generation RNA sequencing (RNA-Seq). Studies demonstrate Tuteva™ has a higher positive predictive value compared to traditional blood biomarkers (Transplant Direct, 2022). More information: VericiDx Tuteva™ https://vericidx.com/.
- Risk assessment for acute rejection at 3, 12, and 24-month post-transplant
- Supports early intervention strategies, minimizing unnecessary biopsies
Results are reported as a quantitative risk score.
Patients are stratified into low-risk and high-risk categories.
Interpretation Caveats:
- A high-risk result suggests elevated probability of acute rejection but is not diagnostic.
- A low-risk result does not entirely exclude rejection but indicates reduced likelihood.
High-risk
- Consider intensified monitoring, potential biopsy.
Low-risk
- Continue standard monitoring protocols.
Not applicable
Whole blood (EDTA).
Stability
- Ambient: up to 48 hours
- Refrigerated: up to 5 days.
- Transplant Direct. 2022 Apr 12;8(5):e1316. [PMID: 35434282]
- Clin J Am Soc Nephrol. 2020 Mar 6;15(3):430-438. [PMID: 32066593]
- Front Immunol. 2022 Dec 19;13:1096881. [PMID: 36601111]
- Lancet. 2016 Sep 3;388(10048):983-93. [PMID: 27452608]